



INDIANA UNIVERSITY

## MELVIN AND BREN SIMON COMPREHENSIVE CANCER CENTER

### Cancer center member participation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023

June 2 - June 6, 2023

Members indicated in **BOLD**; Associated IU researchers, fellows and residents are underlined  
Click the abstract titles for additional details

#### ORAL ABSTRACT SESSIONS

---

##### Long term follow-up analysis of plasma miR371 expression to detect early relapse in patients with clinical stage I testicular germ cell tumors on surveillance.

Oral abstract session | Abstract: 5006 | Session track: Genitourinary Cancer—Prostate, Testicular, and Penile

**Authors:** Lucia Nappi, Neetu Saxena, Sara Pautasso, Sylwia Mazurek, Guliz Ozgun, Catarina Kollmannsberger, Max Trottier Chi, Antoine Morin Coulombe, Maryam Soleimani, Kim N. Chi, Bernhard J. Eigl, Peter C. Black, Alan I. So, Martin Gleave, Sean Kern, Siamak Daneshmand, **Nabil Adra**, **Lawrence H. Einhorn**, Craig R. Nichols, Christian K. Kollmannsberger

Organizations: Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, Vancouver Prostate Centre, Vancouver, BC, Canada, BC Cancer - Vancouver Centre, Vancouver, BC, Canada, BC Cancer, Vancouver, BC, Canada, Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada, BC Cancer, Vancouver Centre, Vancouver, BC, Canada, BC Cancer, Vancouver, BC, Canada, British Columbia Cancer Agency, Vancouver, BC, Canada, Vancouver Prostate Center, University of British Columbia, Vancouver, BC, Canada, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada, University of British Columbia, Vancouver, BC, Canada, Uniformed Services University/ Murtha Cancer Center, Bethesda, MD, University of Southern California, Los Angeles, CA, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Testicular Cancer Commons, Knoxville, TN, BC Cancer, Vancouver Cancer Center, Vancouver, BC, Canada

---

##### Chemotherapy induced peripheral neuropathy (CIPN) due to paclitaxel versus docetaxel in patients with early-stage breast cancer receiving taxane therapy: SWOG S1714.

Oral abstract session | Abstract: 12003 | Session track: Symptoms and Survivorship

**Authors:** Meghna S. Trivedi, Joseph M. Unger, Dawn L. Hershman, Amy Darke, Daniel Louis Hertz, Thomas Brannagan, Stephanie Smith, **Bryan P. Schneider**, William Johnson Irvin,

Amanda Redden Hathaway, Amy C. Vander Woude, Vinay K. Gudena, Norah Lynn Henry, Michael Jordan Fisch

Organizations: Columbia University, New York, NY, Fred Hutchinson Cancer Research Center, Seattle, WA, Fred Hutchinson Cancer Center, Seattle, WA, University of Michigan, Ann Arbor, MI, Columbia University Medical Center, NY, NY, Lewis Cancer & Research Pavilion at St. Joseph's Candler/GA NCORP, Savannah, GA, Indiana University, Indianapolis, IN, Bon Secours Cancer Institute at St. Francis, Midlothian, VA, University Cancer & Blood Center, Athens, GA, Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI, Cone Health Cancer Center, Greensboro, NC, University of Michigan Rogel Cancer Center, Ann Arbor, MI, AIM Specialty Health, Chicago, IL

---

**LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.**

Oral abstract session | Abstract: 8006 | Session track: Hematologic Malignancies

**Authors:** Hans C. Lee, Naresh Bumma, Joshua Ryan Richter, Madhav V. Dhodapkar, James E. Hoffman, **Attaya Suvannasankha**, Jeffrey A. Zonder, Mansi R. Shah, Suzanne Lentzsch, Joseph J. Maly, Jing Christine Ye, Ka Lung Wu, Michelle DeVeaux, Dhruvi Chokshi, Anita Boyapati, Anasuya Hazra, Karen Rodriguez-Lorenc, Glenn Scott Kroog, Yariv J. Houvras, Sundar Jagannath

Organizations: The University of Texas MD Anderson Cancer Center, Houston, TX, The Ohio State University Comprehensive Cancer Center, Columbus, OH, Icahn School of Medicine at Mount Sinai, New York, NY, Emory University School of Medicine, Atlanta, GA, University of Miami Health System, Miami, FL, Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN, Karmanos Cancer Institute, Detroit, MI, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Columbia University Medical Center, New York, NY, Norton Cancer Institute, Louisville, KY, University of Michigan, Ann Arbor, MI, Ziekenhuis Netwerk Antwerpen Stuijvenberg, Antwerp, Belgium, Regeneron Pharmaceuticals, Inc., Tarrytown, NY

---

**Preliminary results from the first-in-child phase II trial (ITCC-054/COG-AAML1921) of bosutinib in pediatric patients with newly diagnosed (ND) chronic myeloid leukemia (CML).**

Oral abstract session | Abstract: 10017 | Session track: Pediatric Oncology

**Authors:** Edoardo Pennesi, Erica Brivio, Marieke E Willemse, Yilin Jiang, Vincent HJ van der Velden, H Berna Beverloo, Chad Hudson, Nyla A Heerema, Luke Kuttschreuter, Jamie Frediani, Susan Spiller, **Sandeep Batra**, Michele Redell, Nicoletta Bertorello, Franco Locatelli, Inge M van der Sluis, Michael Roth, Nobuko Hijya, C Michel Zwaan

Organizations: Erasmus MC, Rotterdam, Netherlands, Prinses Maxima Centrum, Utrecht, Utrecht, Netherlands, Hematologics, Seattle, WA, Ohio State University in Columbus, Columbus, OH, Pfizer R&D UK Ltd, Sandwich, United Kingdom, CHOC Children's Hospital, Orange, CA, East Tennessee Children's Hospital, Knoxville, TN, Riley Hosp for Children, Indiana Univ, Indianapolis, IN, Baylor College of Medicine, Houston, TX, Regina Margherita Children's Hospital, S.C. Oncoematologia Pediatrica, Turin, Italy, IRCCS Bambino Gesù Children's Hospital, Sapienza University of Rome, Rome, Italy, Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands, University of Texas MD Anderson Cancer Center, Houston, TX, Columbia University Medical Center, New York, NY

---

**Incidence round screening performance among women with dense breasts undergoing abbreviated breast MRI and digital breast tomosynthesis (ECOG-ACRIN EA1141).**

Oral abstract session | Abstract: 10502 | Session track: Prevention, Risk Reduction, and Hereditary Cancer

**Authors:** Christiane K. Kuhl, Constantine Gatsonis, Gillian Newstead, Bradley S Snyder, Na An, Ilana F. Gareen, Jennifer T Bergin, Habib Rahbar, Janice S. Sung, Jacobs Jacobs, Jennifer A Harvey, Mary H Nicholson, Robert C Ward, Jacqueline Holt, Andrew Prather, **Kathy Miller**, Mitchell D. Schnall, Christopher E Comstock

Organizations: Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany, Brown University School of Public Health, Providence, RI, University of Chicago Department of Family Medicine, Chicago, IL, Brown University, Providence, RI, UW Cancer Center at ProHealth Care, Waukesha, WI, University of Washington School of Medicine; Fred Hutch Cancer Center, Seattle, WA, Memorial Sloan Kettering Cancer Center, New York, NY, West Michigan Cancer Center, Kalamazoo, MI, University of Rochester, Rochester, NY, The Community Hospital, Munster, IN, Rhode Island Hospital, Providence, RI, Delaware/Christiana Care NCORP, Newark, DE, Gunderson Health System, Lacrosse, WI, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, Hospital of the University of Pennsylvania, Philadelphia, PA

## CLINICAL SCIENCE SYMPOSIUM

---

**BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab.**

Clinical Science Symposium | Abstract: 1012 | Track: Breast Cancer

**Authors:** Amy Sanders Clark, Fengmin Zhao, Paula Klein, Alberto J. Montero, Carla Isadora Falkson, Elisa Krill-Jackson, Kendrith M. Rowland, Sagar D. Sardesai, Jason Anthony Incorvati, Patrick Michael Dillon, Antonio C. Wolff, Houra Loghmani, Richard Trauger, Thomas Charles Heineman, Matthew C. Coffey, **Kathy Miller**

Organizations: University of Pennsylvania, Philadelphia, PA, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Malden, MA, Icahn School of Medicine at Mount Sinai, New York, NY, University Hospitals Seidman Cancer Center, Cleveland, OH, University of Rochester Medical Center Department of Medical Oncology, Rochester, NY, University of Miami Sylvester Cancer Center, Miami, FL, Carle Clinic, Champaign, IL, Ohio State University Comprehensive Cancer Center, Columbus, OH, Fox Chase Cancer Center, Temple University Health System, Doylestown, PA, University of Virginia, Charlottesville, VA, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, Oncolytics Biotech, San Diego, CA, Oncolytics Biotech, Calgary, AB, Canada, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN

## EDUCATION SESSIONS

---

**Creating a Memorable Presentation Through the Integration of Learning Science**

Education session | Track: Professional Development and Education Advances

Presentation 1: How to Make It Stick: Why Learning Science Is Transformative for Teaching

**Presenter and panel moderator: Jennifer Schwartz**

---

**Aligning Germline Cancer Predisposition With Tumor-Based Next-Generation Sequencing**

Education session | Track: Prevention, Risk Reduction, and Hereditary Cancer

Presentation 3: Is Tumor Sequencing Enough to Rule out Inherited Cancer Predisposition?

**Presenter and panel moderator: Bryan P. Schneider**

---

**POSTER SESSIONS**

**The impact of physician gender on patient satisfaction in an academic hematology/oncology practice.**

Poster session | Abstract: 11022, Poster: 475 | Track: Professional Development and Education Advances

**Authors:** Alaina Marie Turchi, Ahmed Bilal Khalid, **Chi Mai Nguyen**, **Jing Su**, **Tarah Jean Ballinger**, **Shadia Ibrahim Jalal**

Organizations: Indiana University, Indianapolis, IN, Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN, Indiana University Simon Cancer Center, Indianapolis, IN

---

**Utilization of circulating tumor DNA (ctDNA) analysis to detect minimal residual disease post-surgery and disease progression in metastatic thymic tumors.**

Poster session | Abstract: 8598, Poster: 225 | Track: Lung Cancer

**Authors:** Fatemeh Ardeshir-Larijani, Karthik Raja Ravichandran, **Bryan P. Schneider**, Milan Radovich, **Rohan Maniar**, **Ashiq Masood**, **Kenneth Kesler**, **Patrick J. Loehrer**

Organizations: Indiana University, Melvin and Bren Simon Cancer Center, Indianapolis, IN, Indiana University School of Medicine, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, Melvin and Bren Simon Cancer Center, Indianapolis, IN, Indiana University Dept of Cardiosurgery, Indianapolis, IN

---

**Association of immune-related adverse events and efficacy outcomes in phase II trial of consolidation nivolumab plus ipilimumab or nivolumab alone after chemoradiation in patients with unresectable stage III non-small-cell lung cancer (NSCLC).**

Poster session | Abstract: 8565, Poster: 192 | Track: Lung Cancer

**Authors:** Cynthia Wei, Sandra K. Althouse, Hirva Mamdani, **Nasser H. Hanna**, **Greg Andrew Durm**

Organizations: Indiana University School of Medicine, Indianapolis, IN, Indiana University, Indianapolis, IN, Barbara Ann Karmanos Cancer Institute, Detroit, MI, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN

---

**Effect of colorectal cancer screening on 1-year mortality and medical costs: Real-world evidence from the largest commercial medical claims database in the US.**

Poster session | Abstract: 10579, Poster: 212 | Track: Prevention, Risk Reduction, and Hereditary Cancer

**Authors:** Chi Mai Nguyen, Jing Su

Organizations: Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, IN

---

**Phase 1b/2 study of abemaciclib combined with chemoimmunotherapy in pediatric and young adult patients with relapsed/refractory neuroblastoma (JPCS Part C).**

Poster session | Abstract: TPS10068, Poster: 373a | Track: Pediatric Oncology

**Authors:** Emily Gustava Greengard, **Melissa Bear**, Bradley DeNardo, Noah Federman, Julie Krystal, Giselle Linda Saulnier Sholler, Yanhong Zhou, Holly Knoderer, Sarah C Nabinger, Lindsey M. Hoffman

Organizations: University of Minnesota, Eden Prairie, MN, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, The Warren Alpert Medical School of Brown University, Providence, RI, David Geffen School of Medicine UCLA, Los Angeles, CA, Cohen Children's Medical Center, New Hyde Park, NY, Levine Children's Hospital at Atrium Health, Charlotte, NC, Eli Lilly and Company, Indianapolis, IN, Eil Lilly and Company, Indianapolis, IN, Phoenix Children's Hospital, Phoenix, AZ

---

**Reduction in Curie score in neuroblastoma patients treated with naxitamab.**

Poster session | Abstract: 10042, Poster: 348 | Track: Pediatric Oncology

**Authors:** Jaume Mora, Godfrey Chi-Fung Chan, Daniel A. Morgenstern, Loredana Amoroso, Karsten Nysom, Joerg Faber, Arthur Wingerter, **Melissa Bear**, Alba Rubio-San-Simón, Brian H. Kushner, Karen Tornøe, Rene DePont Christensen

Organizations: Pediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain, Hong Kong Children's Hospital, The University of Hong Kong, Hong Kong, Hong Kong, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, IRCCS Istituto Giannina Gaslini, Genoa, Italy, Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Copenhagen, Denmark, Center for Pediatric and Adolescent Medicine, University Medical Center of the Johannes Gutenberg University, Mainz, Germany, Riley Hospital for Children at Indiana University Health, Indianapolis, IN, Hospital Infantil Universitario Niño Jesús, Madrid, Spain, Memorial Sloan Kettering Cancer Center, New York, NY, Y-mAbs Therapeutics, Inc., Hørsholm, Denmark, YmAbs A/S, Hørsholm, Denmark

---

**Multimodality, online oncology learning resources: Meeting residents where they are—A pilot to create a new oncology curriculum.**

**5** | IU Simon Comprehensive Cancer Center members indicated in **BOLD**; Associated IU researchers, fellows and residents are underlined

Poster session | Abstract: 11035, Poster: 488 | Track: Professional Development and Education Advances

**Authors:** Jennifer King, Phillip Pham, Ahmed Bilal Khalid, Mohamad Sabra, **Jennifer E. Schwartz**

Organizations: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Indiana University Internal Medicine, Indianapolis, IN, Indiana University, Indianapolis, IN, Indiana University School of Medicine, Indianapolis, IN

---

**A phase I/II study to evaluate the safety, pharmacodynamics, and efficacy of entinostat in combination with atezolizumab and bevacizumab in patients with renal cell carcinoma.**

Poster session | Abstract: 4526, Poster: 18 | Track: Genitourinary Cancer—Kidney and Bladder

**Authors:** Roberto Pili, Naomi B. Haas, Paul Monk, **Theodore F. Logan**, Vivek Narayan, Heather Burney, **Nabil Adra**

Organizations: University at Buffalo, Buffalo, NY, University of Pennsylvania-Abramson Cancer Center, Philadelphia, PA, Ohio State University, Columbus, OH, Indiana University, Indianapolis, IN, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

---

**Evaluating the impact of exercise in women living with indolent metastatic breast cancer: The EMBody trial.**

Poster session | Abstract: TPS12140, Poster: 506b | Track: Symptoms and Survivorship

**Authors:** Martha Cancilla, Donya Nemati, Danielle Halsey, Kelly Shanahan, Lesley Glenn, Keith Avin, Nicole Keith, **Kathy Miller**, Jennifer A. Ligibel, **Tarah Jean Ballinger**

Organizations: IU School of Medicine, Indianapolis, IN, IUPUI School of Health and Human Sciences, Indianapolis, IN, Indiana University School of Medicine, Indianapolis, IN, METAvivor, South Lake Tahoe, CA, Project Life, Central Point, OR, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, Dana-Farber Cancer Institute, Boston, MA, Indiana University Simon Cancer Center, Indianapolis, IN

---

**The impact of population pharmacogenomics and risk allele frequencies on cisplatin-induced peripheral sensory neuropathy (PSN).**

Poster session | Abstract: 12092, Poster: 460 | Track: Symptoms and Survivorship

**Authors:** Swetha Nakshatri, Paul C. Dinh, Darren R. Feldman, Robert James Hamilton, David J. Vaughn, Chunkit Fung, Christian K. Kollmannsberger, Robert A Huddart, Neil E. Martin, **Lawrence H. Einhorn**, Nancy Cox, **Lois B. Travis**, M. Eileen Dolan

Organizations: University of Chicago, Chicago, IL, IU Simon Comprehensive Cancer Center, Indianapolis, IN, Memorial Sloan Kettering Cancer Center, New York, NY, University Health Network, Toronto, ON, Canada, University of Pennsylvania, Philadelphia, PA, University of Rochester School of Medicine & Dentistry, Rochester, NY, University of British Columbia, Vancouver, BC, Canada, Section of Radiotherapy and Imaging, Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, Dana-Farber Cancer Institute, Boston, MA, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Vanderbilt University, Nashville, TN, Indiana University Simon Cancer Center, Indianapolis, IN, Department of Medicine, University of Chicago, Chicago, IL

---

**6** | IU Simon Comprehensive Cancer Center members indicated in **BOLD**; Associated IU researchers, fellows and residents are underlined

---

**Surgically targeted radiation therapy (STaRT) for recurrent glioblastoma: Initial outcomes from a prospective multicenter registry.**

Poster session | Abstract: 2038, Poster: 395 | Track: Central Nervous System Tumors

**Authors:** Ahmad Ozair, David Brachman, Lisa Campbell, Clark C Chen, Toral R. Patel, John Floyd, Devon H Hayden, Adam W Nowlan, Andrea C Wasilewski, John Wanebo, Mitesh Shah, **Angela Richardson**, Simon Hanft, Ondrej Choutka, Colette Shen, Zabi Wardak, Stuart Lee, Tulika Ranjan, Atulya Aman Khosla, Manmeet Singh Ahluwalia

Organizations: Miami Cancer Institute, Baptist Health South Florida, Miami, FL, GT Medical Technologies, Tempe, AZ, University of Minnesota Medical Center, Minneapolis, MN, University of Texas Southwestern Medical Center, Dallas, TX, The University of Texas Health Science Center at San Antonio, San Antonio, TX, BayCare Medical Center, Clearwater, FL, Piedmont Atlanta Hospital, Piedmont Healthcare, Atlanta, GA, Allina Healthcare, Minneapolis, MN, Barrow Neurological Institute, Phoenix, AZ, Indiana University School of Medicine, Indianapolis, IN, Westchester Medical Center, Valhalla, NY, Saint Alphonsus Spine Care, Boise, ID, University of North Carolina at Chapel Hill, Chapel Hill, NC, Vidant Health, Greenville, NC, Tampa General Hospital, Tampa, FL

---

**SWOG S1823/CCTG GCC1: Translational observational investigational study of the liquid biomarker microRNA 371a-3p in newly diagnosed germ cell tumours—Real-world trial design, rapid accrual, and robust secondary use of data opportunities.**

Poster session | Abstract: TPS5103, Poster: 194b | Track: Genitourinary Cancer—Prostate, Testicular, and Penile

**Authors:** Antoine Morin Coulombe, Guliz Ozgun, Rebecca Johnson, Mark Andrew Lewis, **Nabil Adra**, Scott E. Eggener, Bruce J. Roth, Christopher W. Ryan, Christopher Porter, Fred Millard, Thomas Jang, Robert James Hamilton, **Lawrence H. Einhorn**, Christian K. Kollmannsberger, Kathryn B. Arnold, Charles David Blanke, Siamak Daneshmand, Craig R. Nichols, Lucia Nappi, Andrea Harzstark

Organizations: BCCancer, Vancouver, BC, Canada, Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada, Multicare, Tacoma, WA, Intermountain Healthcare, Murray, UT, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Center for Data Intensive Science at the University of Chicago, Chicago, IL, Washington University School of Medicine, St. Louis, MO, OHSU Knight Cancer Institute, Portland, OR, Virginia Mason Medical Center, Seattle, WA, UC San Diego Health, La Jolla, CA, Rutgers, New Brunswick, NJ, University Health Network, Toronto, ON, Canada, University of British Columbia, Vancouver, BC, Canada, SWOG Statistics and Data Management Center, Seattle, WA, SWOG Cancer Research Network Group Chair's Office, Oregon Health and Science University Knight Cancer Institute, Portland, OR, USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Testicular Cancer Commons, Knoxville, TN, Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada, Kaiser Permanente, San Francisco, CA

---

**Identification of genes encoding targets associated with adverse events in multiple myeloma.**

Poster session | Abstract: 1556, Poster: 150 | Track: Care Delivery and Regulatory Policy



**Authors:** Xuan Xu, Shahzad Raza, Nuwan Millagaha Gadara, Remya Ampadi Ramachandran, Jim Riviere, Mobina Golmohammadi, Gerald Wyckoff, Beth Faiman, Faiz Anwer, **Ashiq Masood**, Jack Khouri, Sandra Ann Mazzone, Louis Williams, Leyla Shune, Jianjun Zhao, Christy Joy Samaras, Ata Abbas, Jason Neil Valent, Majid Jaber-Douraki

Organizations: Kansas State University–Olathe, Olathe, KS, Taussig Cancer Center, Cleveland Clinic, Ohio, OH, Kansas State University, Olathe, KS, University of Missouri Kansas City, Kansas City, MO, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, Taussig Cancer Institute, Cleveland, OH, Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, IN, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Division of Hematologic Malignancies and Cellular Therapeutics (HMCT), University of Kansas Medical Center, Kansas City, KS, Cleveland Clinic Lerner Research Institute, Cleveland, OH, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, Case Comprehensive Cancer Center, Cleveland, OH, DATA Consortium, Computational Comparative Medicine, Department of Mathematics, Kansas State University–Olathe, Olathe, KS

---

**A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.**

Poster session | Abstract: TPS4190, Poster: 501b | Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Authors:** Sherise C. Rogers, Ilyas Sahin, Jesus C. Fabregas, Ibrahim Nassour, Brian Hemendra Ramnarain, Kathryn Hitchcock, Steven J. Hughes, Ji-Hyun Lee, Omar Roger Kayaleh, **Anita Ahmed Turk**, Z. Hugh Fan, Karen Bullock Russell, David L. DeRemer, Carmen Joseph Allegra, Thomas J. George

Organizations: University of Florida/UF Health Cancer Center, Gainesville, FL, University of Florida Health Cancer Center, Gainesville, FL, Orlando Health, Orlando, FL, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, University of Florida, Gainesville, FL, Tallahassee Memorial HealthCare, Tallahassee, FL

---

**NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer.**

Poster session | Abstract: TPS623, Poster: 449a | Track: Breast Cancer

**Authors:** Julia R. White, Reena S. Cecchini, Eleanor Elizabeth Harris, Eleftherios P. Mamounas, Daniel G. Stover, Patricia A. Ganz, Reshma Jaggi, Stewart J. Anderson, Carmen Bergom, Valerie Theberge, Mahmoud El-Tamer, **Richard C. Zellars**, Dean Alden Shumway, Guang-Pei Chen, Thomas B. Julian, Norman Wolmark, Annabel Goodwin

Organizations: University of Kansas Medical Center Comprehensive Cancer Center (KUMC CCC), Kansas City, KS, NRG Oncology SDMC, and The University of Pittsburgh, Pittsburgh, PA, St. Luke's University Health Network, Easton, PA, Orlando Health Cancer Institute, Orlando, FL, Ohio State University Comprehensive Cancer Center, Columbus, OH, UCLA Jonsson Comprehensive Cancer Center, UCLA Fielding School of Public Health, Los Angeles, CA, Emory University School of Medicine, Atlanta, GA, University of Pittsburgh, Pittsburgh, PA, Washington University School of Medicine, St. Louis, MO, CHU de Québec – Université Laval, Québec City, QC, Canada, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical School and Alliance, New York, NY, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Mayo Clinic, Rochester, MN, Medical College of Wisconsin, Milwaukee, WI, The Allegheny Health Network Cancer Institute, Pittsburgh, PA, UPMC Hillman Cancer



Center, The University of Pittsburgh School of Medicine, Pittsburgh, PA, Royal Prince Alfred Hospital, Camperdown, Australia

---

**Circulating tumor cells (CTCs) dynamics after CDK4/6i for hormone-receptor positive (HR+) metastatic breast cancer (MBC): A biomarker analysis of the PACE randomized phase II study.**

Poster session | Abstract: 1059, Poster: 280 | Track: Breast Cancer

**Authors:** Lorenzo Gerratana, Yue Ren, Carolina Reduzzi, Meredith M. Regan, Reshma L. Mahtani, Cynthia X. Ma, Angela DeMichele, Jane Lowe Meisel, **Kathy Miller**, Trevor Augustus Jolly, Elizabeth Carlross Riley, Rubina Qamar, Priyanka Sharma, Sonya A. Reid, Naomi Yu Ko, Yuan Liu, Harold J. Burstein, Sara M. Tolaney, Massimo Cristofanilli, Erica L. Mayer

Organizations: CRO Aviano National Cancer Institute, IRCCS, Aviano, Italy, Dana-Farber Cancer Institute, Boston, MA, Weill Cornell Medicine, New York, NY, Miami Cancer Institute, Baptist Health South Florida, Plantation, FL, Washington University School of Medicine, St. Louis, MO, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, Winship Cancer Institute of Emory University, Atlanta, GA, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, University of North Carolina at Chapel Hill, Chapel Hill, NC, University of Louisville, Louisville, KY, Advocate Aurora Health, Milwaukee, WI, University of Kansas Cancer Center, Westwood, KS, Vanderbilt-Ingram Cancer Center, Nashville, TN, Boston University Section of Hematology and Medical Oncology, Boston, MA, Pfizer, Inc., La Jolla, CA

---

**Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2<sup>+</sup> breast cancer.**

Poster session | Abstract: TPS1112, Poster: 322b | Track: Breast Cancer

**Authors:** Shipra Gandhi, Peter A. J. Forsyth, **Mateusz Opyrchal**, Kamran A. Ahmed, Kristopher Attwood, Ellis Glenn Levine, Tracey L. O'Connor, Amy P. Early, Robert Alan Fenstermaker, Dheerendra Prasad, Kazuaki Takabe, Brian J. Czerniecki, Pawel Kalinski

Organizations: Roswell Park Comprehensive Cancer Center, Buffalo, NY, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Indiana University School of Medicine, Indianapolis, IN, Roswell Park Cancer Institute, Buffalo, NY, Moffitt Cancer Center, Tampa, FL

---

**A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2–positive breast cancer.**

Poster session | Abstract: 532, Poster: 362 | Track: Breast Cancer

**Authors:** Hyo S. Han, Robert Wesolowski, **Carla Fisher**, Shipra Gandhi, William R Gwin, Maria J Kowzun, Keerthi Gogineni, Hien Liu, Ricardo L Costa, Julian Guerrero, Stephy Mathew, Michael J. Schell, Hatem Hussein Soliman, Mary L. Disis, Brian J. Czerniecki

Organizations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Ohio State University Wexner Medical Center, Columbus, OH, Indiana University School of Medicine, Indianapolis, IN, Roswell Park Comprehensive Cancer Center, Buffalo, NY, University of Washington, Cancer Vaccine Institute, Seattle, WA,

---

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Emory University Winship Cancer Institute, Atlanta, GA, H. Lee Moffitt Cancer Center, Tampa, FL, University of Washington, Seattle, WA

---

**Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non–small cell lung cancer patients.**

Poster session | Abstract: TPS2677, Poster: 512a | Track: Developmental Therapeutics—Immunotherapy

**Authors:** Prantesh Jain, Alan Hutson, Cayla Janes, Debora S. Bruno, **Greg Andrew Durm**, Ashish Sangal, Bhoomi Mehrotra, Tania Crombet Ramos, Kalet Leon, Grace K. Dy

Organizations: Roswell Park Comprehensive Cancer Center, Buffalo, NY, Roswell Park Comprehensive Cancer Institute, Buffalo, NY, University Hospitals, Case Comprehensive Cancer Center, Cleveland, OH, Department of Hematology/Oncology, IU Simon Comprehensive Cancer, Indianapolis, IN, Catholic Health Systems, West Islip, NY, St. Francis Hospital, Greenvale, NY, Center of Molecular Immunology, Havana, Cuba

---

## **PUBLICATION ONLY**

**Patient perception and adherence to lung cancer screening in those who meet eligibility criteria.**

Publication only | Abstract: e22503 | Track: Prevention, Risk Reduction, and Hereditary Cancer

**Authors:** Sasmith R. Menakuru, Vijaypal S. Dhillon, Amir F. Beirat, **Nasser H. Hanna**

Organizations: Indiana University School of Medicine, Muncie, IN, Department of Hematology/Oncology, IU Simon Comprehensive Cancer, Indianapolis, IN

---

**Bone metastasis in patients with germ-cell tumors: Analysis of survival outcomes and prognostic factors.**

Publication only | Abstract: e17029 | Track: Genitourinary Cancer—Prostate, Testicular, and Penile

**Authors:** Rebecca Hassoun, **Jennifer King**, Sandra K. Althouse, **Nasser H. Hanna**, **Lawrence H. Einhorn**, **Nabil Adra**

Organizations: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN

---

**Trends of female representation in ASCO leadership and abstracts authorship: A detailed review.**

Publication only | Abstract: e23010 | Track: Professional Development and Education Advances

**Authors:** Razan Aljaras, Ahmad Karkash, Vidya Sree Dandu, Ahmad Abdelfattah Alhader

Organizations: Indiana University School of Medicine, Indianapolis, IN, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Indiana University, Indianapolis, IN

---

**Racial and ethnic differences in thymic epithelial tumors: A single-institution retrospective analysis.**

Publication only | Abstract: e20649 | Track: Lung Cancer

**Authors:** Brice Wuthrich, Rohan Maniar, Emily Heldman, Louis Laniak, Hannah Davis, Fatemeh Ardeshir-Larijani, Aaron John Spittler, **Kenneth Kesler**, **Patrick J. Loehrer**

Organizations: Indiana University School of Medicine, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN

---

**An evaluation of cisplatin, doxorubicin, and cyclophosphamide (PAC) compared to other regimens for patients with unresectable or metastatic thymic carcinoma: A single-institution retrospective analysis.**

Publication only | Abstract: e20650 | Track: Lung Cancer

**Authors:** Brice Wuthrich, Rohan Maniar, Emily Heldman, Louis Laniak, Hannah Davis, Fatemeh Ardeshir-Larijani, Aaron John Spittler, **Kenneth Kesler**, **Patrick J. Loehrer**

Organizations: Indiana University School of Medicine, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN

---

**Clostridium difficile infection and immune mediated diarrhea and colitis in patients with cancer on immune checkpoint inhibitors.**

Publication only | Abstract: e14683 | Track: Developmental Therapeutics—Immunotherapy

**Authors:** Ahmed Bilal Khalid, Phillip Pham, Ashley Varqa Maveddat, Geneva Mari Cunningham, Gerardo Calderon, **Nasser H. Hanna**

Organizations: Indiana University, Indianapolis, IN, Indiana University Internal Medicine, Indianapolis, IN, Indiana University School of Medicine, Indianapolis, IN, Mayo Clinic Rochester, Rochester, MN, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN

---

**Real-world data for predictors of PSA response to Lu177-PSMA-617 in metastatic castration resistant prostate cancer.**

Publication only | Abstract: e17044 | Track: Genitourinary Cancer—Prostate, Testicular, and Penile

**Authors:** Rebecca Hassoun, Mark Tann, Justin Sims, Ashleigh Auxier, Sandra K. Althouse, **Jennifer King**, **Nabil Adra**

Organizations: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN

---

**Rates of colorectal cancer screening versus lung cancer screening: Where does the problem lie?**

Publication only | Abstract: e22504 | Track: Prevention, Risk Reduction, and Hereditary Cancer

**Authors:** Sasmith R. Menakuru, Ahmed Salih, Vijaypal S. Dhillon, **Nasser H. Hanna**

Organizations: Indiana University School of Medicine, Muncie, IN, Department of Hematology/Oncology, IU Simon Comprehensive Cancer, Indianapolis, IN

---

**A phase 2 basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MAP2K1/2 ERK1/2, and NF1.**

Publication only | Abstract: e15088 | Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

**Authors:** Fadi Taza, **Greg Andrew Durm**, **Mateusz Opyrchal**, **Shadia Ibrahim Jalal**, Milan Radovich, **Bryan P. Schneider**, **Anita Ahmed Turk**

Organizations: Division of Hematology and Oncology, Indiana University Simon Cancer Center, Indianapolis, IN, Department of Hematology/Oncology, IU Simon Comprehensive Cancer, Indianapolis, IN, Indiana University Simon Cancer Center, Indianapolis, IN, Melvin and Bren Simon Cancer Center, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN

---

**Clinical outcomes in patients with post-chemotherapy residual non-retroperitoneal (RP) disease in non-seminomatous germ-cell tumors (NSGCT).**

Publication only | Abstract: e17027 | Track: Genitourinary Cancer—Prostate, Testicular, and Penile

**Authors:** **Jennifer King**, Ryan Ashkar, **Kenneth Kesler**, Sandra K. Althouse, **Nasser H. Hanna**, **Lawrence H. Einhorn**, **Nabil Adra**

Organizations: Indiana University, Indianapolis, IN, Melvin and Bren Simon Cancer Center, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, Department of Hematology/Oncology, IU Simon Comprehensive Cancer, Indianapolis, IN

---

**The SMILE scale: A pilot study among patients with cancer.**

Publication only | Abstract: e24036 | Track: Symptoms and Survivorship

**Authors:** Laura Vater, Ali Ajrouch, **Patrick O. Monahan**, Laura Jennewein, Yan Han, Ahmad Karkash, **Nasser H. Hanna**

Organizations: IU Simon Cancer Center, Indianapolis, IN, Indiana University School of Medicine Department of Medicine, Indianapolis, IN, Indiana University, Indianapolis, IN, Indiana University School of Medicine, Department of Medicine, Indianapolis, IN, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN

---

**The association of demographic factors and disease stage on palliative care (PC) referral rates and completion of advanced directives in a lung cancer (LC) patient population.**

Publication only | Abstract: e24150 | Track: Symptoms and Survivorship

**Authors:** Ahmad Karkash, Ali Ajrouch, Hussain I Rangoonwala, **Nasser H. Hanna**, Razan Aljaras, Yara Khalifeh, Adel Hajj Ali, Sasmith Menakuru, **Shadia Ibrahim Jalal**

Organizations: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Indiana University School of Medicine Department of Medicine, Indianapolis, IN, IU Hematology/Oncology, Indianapolis, IN, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, Indiana University School of Medicine, Indianapolis, IN, Heart Vascular Thoracic Institute, Cleveland Clinic, Cleveland, OH, Indiana University School of Medicine- Muncie, Muncie, IN, Indiana University Simon Cancer Center, Indianapolis, IN

---

**A randomized, open-label, phase II study of high-dose interleukin 2 vs high-dose interleukin 2 plus entinostat in renal cell carcinoma.**

Publication only | Abstract: e16540 | Track: Genitourinary Cancer—Kidney and Bladder

**Authors:** Roberto Pili, David I. Quinn, Ralph J. Hauke, Timothy Kuzel, Yan Han, **Nabil Adra**, **Theodore F. Logan**

Organizations: University at Buffalo, Buffalo, NY, USC Norris Comprehensive Cancer Center, Keck Medicine of USC, Los Angeles, CA, Nebraska Cancer Specialists - Midwest Cancer Center, Omaha, NE, Rush University Medical Center, Chicago, IL, Indiana University, Indianapolis, IN, Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, IU Simon Comprehensive Cancer Center, Indianapolis, IN

---

**A funder-based comparison of global oncology research led by NCI-designated cancer centers: Results from the 2021 Global Oncology Survey.**

Publication only | Abstract: e18535 | Track: Health Services Research and Quality Improvement

**Authors:** Elise M. Garton, Linsey Eldridge, Mishka K. Cira, Allison Frank, **Patrick J. Loehrer**, Kalina Duncan

Organizations: Center for Global Health, National Cancer Institute, National Institutes of Health, Rockville, MD, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN

---

**Establishing clinical performance characteristics for Duoseq, a new assay for DNA and RNA sequencing.**

Publication only | Abstract: e15059 | Track: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

**Authors:** Elizabeth Thacker, **Magdalena Czader**, Lin Wang, Eric Hsi, Christopher Giauque, Matthew Sperling, Andrea Vrydaghs, Jordan Bouldin, Robert Erno, Lanie Happ, Clay Parker, **Sandeep Dave**

Organizations: Data Driven Bioscience, Durham, NC, Indiana University, Indianapolis, IN, Wake Forest School of Medicine, Winston-Salem, NC, Wake Forest University, Winston-Salem, NC, Indiana University Hospital, Indianapolis, IN, Duke University, Durham, NC

---

**13** | IU Simon Comprehensive Cancer Center members indicated in **BOLD**; Associated IU researchers, fellows and residents are underlined

---

## **Clinical outcomes with frontline immunotherapy (IO) in BRAF-mutant NSCLC.**

Publication only | Abstract: e21089 | Track: Lung Cancer

**Authors:** Julian A. Marin-Acevedo, Ram Thapa, Sonam Puri, James Kevin Hicks, Jhanelle Elaine Gray

Organizations: Indiana University, Indianapolis, IN, Moffitt Cancer Center, Tampa, FL, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

## **TYPES OF PRESENTATIONS**

---

The ASCO Scientific Program Committee chooses abstracts for the annual meeting and determines presentation format for each accepted abstract. The presentation types include:

**Oral Abstract Sessions:** This type of session includes 12-minute presentations of abstracts representing important clinical and translational research findings by topic category. Experts in the field are chosen to provide comprehensive 12-minute themed discussions of the findings from predetermined abstracts.

**Clinical Science Symposia:** Clinical Science Symposia provide foundational education on a specific topic combined with the presentation and discussion of relevant abstracts. Novel science is put into appropriate context, including assessment of applicability to clinical practice and the need for further research. Presenting authors give 12-minute oral presentations.

**Poster Discussion Sessions:** Each track-based poster discussion session is 90 minutes and highlights 12 abstracts from the poster session held earlier in the day. Four invited discussants each provide a 12-minute discussion placing the selected abstracts in context, with a focus on how the findings apply to clinical practice and future research.

**Poster Sessions:** Selected abstracts are grouped by topic and displayed on poster boards for 3 hours. The Poster Sessions include Trials in Progress abstracts within each track, designed to facilitate awareness of open, ongoing clinical trials of any phase.

**Publication-Only Abstracts:** Quality abstracts that are not selected by the ASCO Scientific Program Committee for presentation at the Annual Meeting may be chosen for inclusion online in the 2022 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology supplement.

*Source: 2023 ASCO Annual Meeting, <https://conferences.asco.org/am/abstract-selection-process-presentations>*